The start of sales of Epicele in Brazil has been completed, with sales scheduled to begin in Q4 2026. Revenue is reflected in the FY2026 financial statements, and milestone income is also anticipated.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4597","jir_company_name":"Sorejiah Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4597-20260714-01.pdf","jir_short_summary":"The start of sales of Epicele in Brazil has been completed, with sales scheduled to begin in Q4 2026. Revenue is reflected in the FY2026 financial statements, and milestone income is also anticipated.","jir_summary":"### Performance Overview\nThis document reports the completion of registration for the start of sales of Epicele in Brazil and the plan to begin sales from Q4 2026. Sales are expected to be reflected in the consolidated results for FY2026, and milestone income is also scheduled to be received. The sales revenue forecast has already been announced.\n\n### Future Outlook and Impact on Revenue\nThe initiation of sales in Brazil is expected to advance the monetization of Epicele. In FY2026, sales revenue will be recorded, and milestone income will be earned, contributing to expected revenue growth. However, specific sales figures and revenue amounts have not been disclosed.","jir_financial_highlights":"Completion of registration for the start of sales of Epicele in Brazil: Completed (Unknown)\nRevenue forecast for Epicele sales in FY2026: Unknown (Already announced)\nMilestone income: Unknown (Scheduled)","jir_category":"","jir_hashtags":"#SorejiahPharma, #FinancialResults, #JapaneseStocks","jir_key_figures":"Completion of registration for the start of sales of Epicele in Brazil\nRevenue forecast for Epicele sales in FY2026 has already been announced\nMilestone income is scheduled to be recognized in the third quarter of this fiscal year","jir_meta_title":"\u3010Sorejiah Pharma\u3011Start of Sales of Epicele in Brazil and Revenue Outlook\uff5cJuly 2026","jir_meta_description":"Sorejiah Pharma has completed the launch of Epicele in Brazil, with revenue reflecting in FY2026. Milestone income is also expected. Important financial results information.","jir_og_title":"\u3010Sorejiah Pharma\u3011Start of Sales of Epicele in Brazil and Revenue Outlook\uff5cJuly 2026","jir_og_description":"\u901f\u5831: Epicele's sales in Brazil and FY2026 revenue outlook. Milestone income is also anticipated, contributing to future performance.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59381,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-80212","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n